PIP Search Page

Displaying 1 - 20 of 107

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check Sort descending	Date Published
MHRA-100055-PIP01-21	Edaravone	Treatment of Amyotrophic lateral sclerosis	Radicava Radicut Radicut Radicut	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	03/11/2021
MHRA-100173-PIP01-21	PACLITAXEL	Treatment of soft tissue sarcoma	Paxorlea	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/11/2021
MHRA-100174-PIP01-21	Encequidar	Treatment of breast cancer Treatment of soft tissue sarcoma	Paxorlea	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/11/2021
MHRA-100152-PIP01-21	cosibelimab	Treatment of cutaneous squamous cell carcinoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	03/12/2021
MHRA-100074-PIP01-21	GABAPENTIN	Treatment of Postherpetic Neuralgia	Gralise	Neurology Pain	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100081-PIP01-21	Zibotentan DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE	Treatment of Chronic Kidney Disease	Not available at present	Other: Renal Disease	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100131-PIP01-21	ATEZOLIZUMAB	Treatment of all malignant neoplasms (except CNS tumours, haematopoietic, lymphoid neoplasms)	Tecentriq Tecentriq Tecentriq Tecentriq	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100142-PIP01-21	Synthetic Hypericin	Treatment of cutaneous T-cell lymphoma	HyBryte	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100080-PIP01-21	Anti-C1s Humanized IgG4 Monoclonal Antibody	Treatment of Immune Thrombocytopenic Purpura		Neurology Immunology -Rheumatology-Transplantation Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/12/2021
MHRA-100112-PIP01-21	savolitinib	Treatment of renal neoplasms	Not available	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100107-PIP01-21	1-(3-methylbutanoyl)-l-aspartyl-l-threonyl-l-histidyl-l-phenylalanyl-l-prolyl-(l-cystinyl-l-isoleucyl-[(n6-(s)-4-carboxy-4-palmitamidobutanoyl)-l-lysinyl]-l-phenylalanyl-l-glutamyl-l-prolyl-l-arginyl-l-serinyl-l-lysinyl-l-glycinyl-l-cystinyl)-l-lysinamide, disulfide, acetate	Treatment of polycythaemia vera		Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100155-PIP01-21	efgartigimod alfa	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100163-PIP01-21	Vupanorsen (PF-07285557)	Treatment of Hypertriglyceridemia Prevention of cardiovascular events	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	18/03/2022
MHRA-100279-PIP01-21	Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide	Diabetic retinopathy		Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No	04/05/2022
MHRA-100368-PIP01-21	aumolertinib	Treatment of lung cancer	Ameile	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100135-PIP01-21	anti-CD40L humanized monoclonal antibody (SAR441344)	Treatment of Sjogren's Syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100184-PIP01-21	BENRALIZUMAB	Non-cystic fibrosis bronchiectasis with an eosinophilic phenotype	FASENRA FASENRA FASENRA FASENRA FASENRA FASENRA	Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100204-PIP01-21	verdiperstat	Treatment of Amyotrophic lateral sclerosis	Dazluma	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100194-PIP01-21	sivopixant	Treatment of unexplained or refractory chronic cough		Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100206-PIP01-21	EMPAGLIFLOZIN	Treatment of ischaemic heart disease	Jardiance Jardiance	Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022

Download XLSX

Search Filters: